PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Cancer Research UK Centre for Drug Development, London, UK. sarah.halford@cancer.org.uk.\', \'Cancer Research UK Centre for Drug Development, London, UK.\', \'Latus Therapeutics, London, UK.\', \'University of Oxford, Oxford, UK.\', \'Oxford University Hospitals NHS Foundation Trust, Oxford, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.\', \'The University of Edinburgh, Edinburgh, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-021-05461-9
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 34412682
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34412682>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34412682>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all